Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model.
M2 macrophages
MDSC
Neutrophil
Smac
Tumor microenvironment
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
23 02 2022
23 02 2022
Historique:
received:
11
10
2021
accepted:
01
02
2022
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma is a major factor that limits the benefits of immunotherapy, especially immune checkpoint blockade. One viable strategy for reverting the immunosuppressive conditions is the use of an oncolytic virus (OV) in combination with other immunotherapy approaches. Infection of PDAC cells with a robust OV can change the tumor microenvironment and increase tumor antigen release by its lytic activities. These changes in the tumor may improve responses to immunotherapy, including immune checkpoint blockade. However, a more potent OV may be required for efficiently infecting pancreatic tumors that may be resistant to OV. Vesicular stomatitis virus, a rapid replicating OV, was armed to express the Smac protein during virus infection (VSV-S). Adaptation by limited dilution largely increased the selective infection of pancreatic cancer cells by VSV-S. The engineered OV was propagated to a large quantity and evaluated for their antitumor activities in an animal model. In a syngeneic KPC model, intratumoral injection of VSV-S inhibited tumor growth, and induced increasing tumor infiltration of neutrophils and elimination of myeloid derived suppressor cells and macrophages in the tumor. More importantly, M2-like macrophages were eliminated preferentially over those with an M1 phenotype. Reduced levels of arginase 1, TGF-β and IL-10 in the tumor also provided evidence for reversion of the immunosuppressive conditions by VSV-S infection. In several cases, tumors were completely cleared by VSV-S treatment, especially when combined with anti-PD-1 therapy. A long-term survival of 44% was achieved. The improved OV, VSV-S, was shown to drastically alter the immune suppressive tumor microenvironment when intratumorally injected. Our results suggest that the combination of potent OV treatment with immune checkpoint blockade may be a promising strategy to treat pancreatic cancer more effectively.
Sections du résumé
BACKGROUND
The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma is a major factor that limits the benefits of immunotherapy, especially immune checkpoint blockade. One viable strategy for reverting the immunosuppressive conditions is the use of an oncolytic virus (OV) in combination with other immunotherapy approaches. Infection of PDAC cells with a robust OV can change the tumor microenvironment and increase tumor antigen release by its lytic activities. These changes in the tumor may improve responses to immunotherapy, including immune checkpoint blockade. However, a more potent OV may be required for efficiently infecting pancreatic tumors that may be resistant to OV.
METHODS
Vesicular stomatitis virus, a rapid replicating OV, was armed to express the Smac protein during virus infection (VSV-S). Adaptation by limited dilution largely increased the selective infection of pancreatic cancer cells by VSV-S. The engineered OV was propagated to a large quantity and evaluated for their antitumor activities in an animal model.
RESULTS
In a syngeneic KPC model, intratumoral injection of VSV-S inhibited tumor growth, and induced increasing tumor infiltration of neutrophils and elimination of myeloid derived suppressor cells and macrophages in the tumor. More importantly, M2-like macrophages were eliminated preferentially over those with an M1 phenotype. Reduced levels of arginase 1, TGF-β and IL-10 in the tumor also provided evidence for reversion of the immunosuppressive conditions by VSV-S infection. In several cases, tumors were completely cleared by VSV-S treatment, especially when combined with anti-PD-1 therapy. A long-term survival of 44% was achieved.
CONCLUSIONS
The improved OV, VSV-S, was shown to drastically alter the immune suppressive tumor microenvironment when intratumorally injected. Our results suggest that the combination of potent OV treatment with immune checkpoint blockade may be a promising strategy to treat pancreatic cancer more effectively.
Identifiants
pubmed: 35197076
doi: 10.1186/s12985-022-01757-7
pii: 10.1186/s12985-022-01757-7
pmc: PMC8867845
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Informations de copyright
© 2022. The Author(s).
Références
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
pubmed: 15299374
Onco Targets Ther. 2014 Feb 04;7:187-92
pubmed: 24523592
Cancers (Basel). 2019 Apr 19;11(4):
pubmed: 31010242
J Gastrointest Cancer. 2019 Jun;50(2):207-213
pubmed: 30891677
PLoS One. 2014 Jul 10;9(7):e102365
pubmed: 25010337
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799479
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7306-11
pubmed: 23589850
Hum Gene Ther. 2010 Apr;21(4):451-62
pubmed: 19911974
Cytokine Growth Factor Rev. 2020 Dec;56:141-148
pubmed: 32859494
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32843336
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Gut. 2018 Feb;67(2):320-332
pubmed: 27797936
Therap Adv Gastroenterol. 2020 Aug 21;13:1756284820948773
pubmed: 32913444
Cancer Res. 2003 Oct 1;63(19):6463-8
pubmed: 14559838
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33082167
Oncotarget. 2016 Nov 29;7(48):79828-79841
pubmed: 27806313
Mol Ther Oncolytics. 2019 Jun 04;14:188-195
pubmed: 31312717
BMC Cancer. 2017 Aug 29;17(1):576
pubmed: 28851316
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Mol Cancer Ther. 2021 Jan;20(1):150-160
pubmed: 33037138
Cancer Gene Ther. 2011 Nov;18(11):785-94
pubmed: 21869820
J Virol. 2020 Jan 17;94(3):
pubmed: 31694943
Immunity. 2017 Aug 15;47(2):323-338.e6
pubmed: 28813661
Biomaterials. 2021 Feb;269:120635
pubmed: 33422940
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Front Immunol. 2020 Nov 10;11:605619
pubmed: 33304355
Adv Exp Med Biol. 2020;1224:117-140
pubmed: 32036608
Gastroenterology. 2020 Jul;159(1):306-319.e12
pubmed: 32179091
Cancer Res. 2013 May 15;73(10):3007-18
pubmed: 23514705
Front Oncol. 2020 Dec 10;10:581457
pubmed: 33363012
World J Gastroenterol. 2018 May 28;24(20):2137-2151
pubmed: 29853732
Cells. 2020 Nov 12;9(11):
pubmed: 33198201
Clin Cancer Res. 2003 Feb;9(2):555-61
pubmed: 12576418
Mol Ther. 2021 Feb 3;29(2):744-761
pubmed: 33130310
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
J Immunol. 2012 Feb 1;188(3):1002-10
pubmed: 22180616
Cancer Discov. 2020 Mar;10(3):422-439
pubmed: 31911451
Gastroenterology. 2015 Jul;149(1):201-10
pubmed: 25888329
J Virol. 2010 May;84(10):4960-8
pubmed: 20181701
Cancer Treat Rev. 2017 Nov;60:32-43
pubmed: 28869888
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217766
Cancer Res. 2020 Nov 1;80(21):4754-4767
pubmed: 32816859
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
Cancer Treat Rev. 2021 May;96:102180
pubmed: 33812339
Nephron Clin Pract. 2013;123 Suppl 1:29-54
pubmed: 23774485
Front Immunol. 2020 May 15;11:938
pubmed: 32499785